http://www.arrayit.com/Microarray_Diagnostics/Park
Post# of 30028
Posted On: 10/01/2014 8:01:10 PM
http://www.arrayit.com/Microarray_Diagnostics...sease.html
Arrayit analyzed 31,500,000 H25K gene expression data points from 18 patients with Parkinson’s Disease using Arrayit Genome Pathway Builder™ (GPB) software, which utilized multivariate calculus, fuzzy logic and artificial intelligence to construct a biological pathway for Parkinson’s Disease. Biological pathway construction was helpful because it provided a molecular basis for PD and will allow a targeted approach to the discovery and testing of therapeutic proteins and drugs including mesencephalic astrocyte-derived neurotrophic factor (MANF).
Arrayit bioinformatic analysis of 18 Parkinson’s patients using Genome Pathway Builder™ (GPB) software allowed us to construct a best-fit biological pathway for Parkinson’s Disease. The modeled pathway responsible for PD symptoms appears to involve a cellular malfunction in the pathway that mediates protein folding, misfolding and removal inside human cells. This model is provocative because it is consistent with the neuropathology observed in Parkinson’s patients whereby accumulated protein aggregates disrupt the function of the dopaminergic cells comprising the substantia nigra. The promising protein therapeutic lead compound mesencephalic astrocyte-derived neurotrophic factor (MANF) appears to work by exerting its mode of action on the same biological pathway.
Parkinson’s Disease Therapeutics
Several companies are developing small molecule and protein therapeutics for Parkinsons’ Disease. The Arrayit PDx™ Test provides a molecular assay for benchmarking and optimizing PD medicines and targeting treatment to bona fide PD patients.
Arrayit analyzed 31,500,000 H25K gene expression data points from 18 patients with Parkinson’s Disease using Arrayit Genome Pathway Builder™ (GPB) software, which utilized multivariate calculus, fuzzy logic and artificial intelligence to construct a biological pathway for Parkinson’s Disease. Biological pathway construction was helpful because it provided a molecular basis for PD and will allow a targeted approach to the discovery and testing of therapeutic proteins and drugs including mesencephalic astrocyte-derived neurotrophic factor (MANF).
Arrayit bioinformatic analysis of 18 Parkinson’s patients using Genome Pathway Builder™ (GPB) software allowed us to construct a best-fit biological pathway for Parkinson’s Disease. The modeled pathway responsible for PD symptoms appears to involve a cellular malfunction in the pathway that mediates protein folding, misfolding and removal inside human cells. This model is provocative because it is consistent with the neuropathology observed in Parkinson’s patients whereby accumulated protein aggregates disrupt the function of the dopaminergic cells comprising the substantia nigra. The promising protein therapeutic lead compound mesencephalic astrocyte-derived neurotrophic factor (MANF) appears to work by exerting its mode of action on the same biological pathway.
Parkinson’s Disease Therapeutics
Several companies are developing small molecule and protein therapeutics for Parkinsons’ Disease. The Arrayit PDx™ Test provides a molecular assay for benchmarking and optimizing PD medicines and targeting treatment to bona fide PD patients.
(0)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼